Survival outcomes post non-invasive ventilation (NIV) initiation in motor neurone disease (MND)

Introduction: MND has a median survival of 3 years and can be classified as limb, bulbar, or respiratory onset. Little is known about the effect of NIV on survival in MND. Aims: This study investigates survival outcomes and hospitalisation in NIV treated MND patients. Methods: This retrospective study recorded MND patients diagnosed from January 2015-September 2023 at a United Kingdom tertiary hospital. Internal database identified patients with: MND diagnosis, death, and NIV treatment. Comparative analysis was performed using survival curves, Chi Squared and Wilcoxon tests. Results: 226 MND patients were identified. Mean age 70. 86 (38%) patients had bulbar, 127 (56%) had limb, and 10 (4%) had respiratory onset MND. Median survival was 12 months (IQR 17). 142 patients commenced NIV following diagnosis. NIV treated patients had longer survival vs no NIV (median 13.5 vs 8 months) but was not significant, p=0.3371. NIV treated patients had significantly fewer hospitalisations in the last 12 months of life vs no NIV (70% vs 30% with 0 admissions) p=0.0056. Bulbar onset NIV treated patients had longer survival vs respiratory onset, although respiratory onset NIV group was small (n=9) p=0.0025 (figure 1). erjor;12/suppl_17/96/F1 F1 F1 Conclusion: NIV initiation increased median survival in MND patients but was not significant. NIV treated patients had significantly fewer hospitalisations in the last 12 months and remains an effective therapy for MND patients.